Previous reports on blockade of NLRP3 with this specific NLRP3 inhibitor effectively limited the induction of DSS colitis in mice (28), and inhibits NF-κB, IL-1β, caspase-1 and MPO activity (25). Here, NFKB1 is linked to colitis.